News for Lee's Pharmaceutical Holdings Limited (0950.HK)

Published at

Nov 8, 2022 5:34 AM

by seekingalpha.com

mixed

mixed

Sorrento Therapeutics: Down The Rabbit Hole (NASDAQ:SRNE)

While its CEO bruits a future market cap of hundreds of billions, Sorrento's current cap is angling down to <$0.7 billion. See why I rate SRNE stock a Hold.

SRNE 0950.HK

Read more →
Published at

Oct 25, 2022 7:50 AM

by etfdailynews.com

mixed

mixed

Windtree Therapeutics (NASDAQ:WINT) & NanoString Technologies (NASDAQ:NSTG) Critical Contrast

Read Windtree Therapeutics (NASDAQ:WINT) & NanoString Technologies (NASDAQ:NSTG) Critical Contrast at ETF Daily News

WINT NSTG WINTW 0950.HK LRCX.MX LRCX LAR.DE L1RC34.SA 0JT5.L

Read more →
Published at

Oct 1, 2022 7:36 AM

by etfdailynews.com

mixed

mixed

Critical Comparison: Windtree Therapeutics (NASDAQ:WINT) & BioNTech (NASDAQ:BNTX)

Read Critical Comparison: Windtree Therapeutics (NASDAQ:WINT) & BioNTech (NASDAQ:BNTX) at ETF Daily News

WINTW WINT SFOSF REGN34.SA REGN.MX REGN PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE GNMSF GMABN.MX GMAB BNTXN.MX BNTX 2196.HK 0R2M.L 0A3M.L 0950.HK

Read more →
Published at

Jul 9, 2022 7:46 AM

by etfdailynews.com

mixed

mixed

Head-To-Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) & Windtree Therapeutics (NASDAQ:WINT)

Read Head-To-Head Contrast: Iovance Biotherapeutics (NASDAQ:IOVA) & Windtree Therapeutics (NASDAQ:WINT) at ETF Daily News

WINTW WINT 0950.HK IOVA 0JDK.L CMVLF CLLS ALCLS.PA

Read more →
Published at

Jun 27, 2022 8:26 AM

by etfdailynews.com

mixed

mixed

Windtree Therapeutics (NASDAQ:WINT) & Innate Pharma (NASDAQ:IPHA) Head-To-Head Comparison

Read Windtree Therapeutics (NASDAQ:WINT) & Innate Pharma (NASDAQ:IPHA) Head-To-Head Comparison at ETF Daily News

WINTW WINT NVON.MX NVO NOVOBN.MX NOVC.DE NOVA.DE NONOF IPHYF IPHA IPH.PA 0TDD.L 0950.HK

Read more →
Published at

Jun 17, 2022 8:16 PM

by etfdailynews.com

mixed

mixed

Critical Survey: Windtree Therapeutics (NASDAQ:WINT) versus Krystal Biotech (NASDAQ:KRYS)

Read Critical Survey: Windtree Therapeutics (NASDAQ:WINT) versus Krystal Biotech (NASDAQ:KRYS) at ETF Daily News

WINT KRYS 0950.HK WINTW

Read more →
Published at

May 19, 2022 12:24 AM

by etfdailynews.com

mixed

mixed

Reviewing Immunovant (NASDAQ:IMVT) and Windtree Therapeutics (NASDAQ:WINT)

Read Reviewing Immunovant (NASDAQ:IMVT) and Windtree Therapeutics (NASDAQ:WINT) at ETF Daily News

WINTW WINT IMVT 0950.HK

Read more →
Published at

May 18, 2022 12:14 PM

by etfdailynews.com

mixed

mixed

Windtree Therapeutics (NASDAQ:WINT) vs. Vigil Neuroscience (NASDAQ:VIGL) Financial Review

Read Windtree Therapeutics (NASDAQ:WINT) vs. Vigil Neuroscience (NASDAQ:VIGL) Financial Review at ETF Daily News

WINTW WINT 0950.HK

Read more →
Published at

May 12, 2022 7:02 AM

by etfdailynews.com

mixed

mixed

Head-To-Head Contrast: Windtree Therapeutics (NASDAQ:WINT) vs. Autolus Therapeutics (NASDAQ:AUTL)

Read Head-To-Head Contrast: Windtree Therapeutics (NASDAQ:WINT) vs. Autolus Therapeutics (NASDAQ:AUTL) at ETF Daily News

WINTW WINT AUTL 0950.HK

Read more →
Published at

Apr 15, 2022 6:04 PM

by etfdailynews.com

mixed

mixed

Windtree Therapeutics (NASDAQ:WINT) and Organovo (NASDAQ:ONVO) Head-To-Head Contrast

Read Windtree Therapeutics (NASDAQ:WINT) and Organovo (NASDAQ:ONVO) Head-To-Head Contrast at ETF Daily News

WINTW WINT ONVO 0950.HK 0R02.L

Read more →
Published at

Nov 1, 2021 2:00 PM

by thestreet.com

mixed

mixed

Sorrento's License Partner, Lee's Pharmaceutical Announces NDA Filing Acceptance By NMPA For Anti-PD-L1 Antibody Socazolimab For Treatment Of Recurrent Or Metastatic Cervical Cancer

Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee's Pharma. China National Medical Products

0950.HK SRNE 6622.HK 0L85.L

Read more →
Published at

Jul 23, 2021 5:37 PM

by thestreet.com

neutral

neutral

Lee's Pharmaceutical Announces First Patient Dosed With Its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, As A First-Line Treatment Of Extensive-Stage Small-Cell Lung Cancer

China Oncology Focus, a subsidiary of Lee's Pharm, has enrolled the first patient in the Socazolimab double-blinded Phase 3 study in combination with

SRNE 6622.HK 0L85.L 0950.HK

Read more →